Vers des essais cliniques ?
What about XOMA's peptides? Screening peptides for antimicrobials is a brilliant idea, but we will have to see what
happens in that search. This new BPI-derived peptide compound appears to be very active in vitro and in vivo against Candida and other fungi. Such data on a peptide derived from a compound that is already being given to humans with relatively low toxicity shows great promise
(Jack Remington, M.D., Stanford University, Cal.)
NEUPREX®, XOMA’s first recombinant BPI-derived product, completed a Phase III trial in severe pediatric meningococcemia in May 1999 and is in Phase I for cystic fibrosis patients (15 patients)